Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma

Mian Xi(The University of Texas MD Anderson Cancer Center), Steven H. Lin(The University of Texas MD Anderson Cancer Center), Christopher L. Hallemeier(Mayo Clinic in Arizona), Reza J. Mehran(The University of Texas MD Anderson Cancer Center), Manoop S. Bhutani(Medical University of South Carolina), Ritsuko Komaki(The University of Texas MD Anderson Cancer Center), Dipen M. Maru(The University of Texas MD Anderson Cancer Center), Brian Weston(The University of Texas MD Anderson Cancer Center), Zhongxing Liao(Thoracic Surgery Foundation), Kenneth W. Merrell(Mayo Clinic), Mariela A. Blum Murphy(The University of Texas MD Anderson Cancer Center), Linus Ho(The University of Texas MD Anderson Cancer Center), Jeffrey H. Lee(Kaiser Permanente San Francisco Medical Center), Wayne L. Hofstetter(The University of Texas MD Anderson Cancer Center), Jaffer A. Ajani(The University of Texas MD Anderson Cancer Center)
Annals of Surgery
June 17, 2017
10.1097/sla.0000000000002352
Cited by 46

Related Papers

Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.7k
Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.1k
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet|2023|701
Integrating genomic features for non-invasive early lung cancer detection
|Nature|2020|689